Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority to CU20100014ApriorityCriticalpatent/CU20100014A7/en
Publication of CU20100014A7publicationCriticalpatent/CU20100014A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a un compuesto de la fórmula (I) ESPACIO PARA LA FÓRMULA o una sal, adecuadamente una sal farmacéuticamente aceptable, o solvato del mismo, donde los grupos R1, R2, Ar´, A y B son definidos en la descripción, a composiciones y uso de los compuestos en el tratamiento de enfermedades mejoradas por la inhibición de fosfatidilinositol 3-cinasa.The present invention relates to a compound of the formula (I) FORMULA SPACE or a salt, suitably a pharmaceutically acceptable salt, or solvate thereof, where the groups R1, R2, Ar ', A and B are defined in the description, compositions and use of the compounds in the treatment of diseases enhanced by the inhibition of phosphatidylinositol 3-kinase.
CU20100014A2010-01-262010-01-26
USEFUL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC DISEASES
CU20100014A7
(en)
Compounds derived from bis (fluoroalkyl) -1,4-benzodiazepinone, notch inhibitors; crystalline compound; pharmaceutical composition that includes them; pharmaceutical combination; and its use for the treatment of cancer.
Compounds derived from pyridin-4-yl-thiazol-2-amide 2-amide-pyrrolidin-1,2-dicarboxylic, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of a medicament for the treatment of cancer.